CMS Russia has advised Ovoca Bio Plc on its acquisition of a controlling stake in IVIX, a Russian biomedical R&D company.
The transaction represents a strategic move by Ovoca and an opportunity to tap into the unique potential of the global demand for novel reproductive health products. Fuelled by the creativity of its researchers and the funding provided by Ovoca, IVIX is looking to develop an effective medicinal product and, following completion of the required clinical trials, to put it on the Russian and other markets.
The CMS team was led by a corporate partner and head of M&A Vladimir Zenin who was supported by associates Mikhail Panferov, Vladislav Eltovskiy and Nikolai Molostov.
Vladimir has commented: “We have been thrilled to advise Ovoca on this exciting move which is transformative for the company and opens a whole new era for Ovoca’s shareholders and other investors. This deal underscores CMS’ dedication to the life sciences sector, showcases the versatility of our platform and reconfirms our agility and commitment to being our clients’ “first choice” for implementation of their most ambitious plans.”